OBJECTIVE: To rapidly evaluate the efficacy

safety and economical efficiency of ivabradine hydrochloride in treatment of heart failure by rapid health technology assessment（HTA）. METHODS: PubMed

the Cochrane Library

CNKI

Wanfang Data were retrieved to collect the HTA reports

systematic reviews/Meta-analysis and pharmacoeconomic studies related to ivabradine hydrochloride in treatment of heart failure. Two evaluators independently screened the literature according to inclusion and exclusion criteria

literature quality was evaluated and analyzed. RESULTS: A total of 8 systematic reviews/Meta-analysis and 7 pharmacoeconomic studies were enrolled. Compared with standard therapy

ivabradine hydrochloride combined with standard therapy can significantly reduce the patients’ heart rate and N-terminal pro-B-type natriuretic peptide level

reduce left ventricular end-diastolic diameter

reduce left ventricular end-diastolic and end-systolic volumes

reduce ventricular end-systolic volume index

improved left ventricular ejection fraction

6-min walking test distance

quality of life and activity tolerance

yet had no significant effect on all-cause mortality

cardiovascular mortality

and hospitalization for heart failure. The incidence of adverse drug reactions in patients in the ivabradine hydrochloride group was similar to that in the control group. Ivabradine hydrochloride had more cost-effectiveness advantages. CONCLUSIONS: It is effective

safe and economical for ivabradine hydrochloride in the treatment of heart failure to improve cardiac function. More high-quality studies should be carried out to explore its clinical value.